Santen Pharmaceutical: Report on the Status of Purchases of Treasury Stock by the Company (Based on Article 24-6, Paragraph 1 of the Law)
Santen Pharmaceutical: Santen will report its consolidated performance for the first quarter of fiscal year 2024.
Santen Pharmaceutical: March 2025 quarterly earnings report [IFRS] (consolidated)
Santen Pharmaceutical: Santen announces the status of their share buyback.
Santen Pharmaceutical: Announcements of individual stock buyback status.
Santen Pharmaceutical: Corporate Governance Report
Santen Pharmaceutical: Report on Corporate Governance as of July 31, 2024.
Change report (exemption share certificates, etc.)
Santen Pharmaceutical: Announcements of individual stocks: Notice of completion of disposal of treasury stock based on restricted stock linked compensation program.
Santen Pharmaceutical: Announcements of individual stocks regarding the completion of payment for the disposal of treasury stock as restricted stock compensation.
Santen Pharmaceutical: Report on the Status of Purchases of Treasury Stock by the Company (Based on Article 24-6, Paragraph 1 of the Law)
Santen Pharmaceutical: Corporate Governance Report
Santen Pharmaceutical: Corporate Governance Report 07/01/2024
Santen Pharmaceutical: Santen announces the status of their share buyback.
Santen Pharmaceutical: Announcements of individual stock buyback status.
Santen Pharmaceutical: Interim report
Santen Pharmaceutical: Announcements of individual stocks regarding disposal of treasury stock as share-based compensation with transfer restrictions.
Santen Pharmaceutical: Announcements of individual stocks regarding the disposal of treasury stocks based on stock-linked compensation program.
Santen Pharmaceutical: Extraordinary Report
Santen Pharmaceutical: Internal Control Report - 112 (2023/04/01 - 2024/03/31)
No Data